Thailand: In a landmark move at the World Diabetes Congress 2025 in Bangkok, the International Diabetes Federation (IDF) ...

The new type 5 diabetes has often been misunderstood and wrongly grouped under type 1 or type 2 diabetes. With growing research, the disease has been given its own category.

In diabetes care, AI has propelled the field forward through predictive modeling, decision support, and real-time glycemic ...

This summary of health news briefs includes reports on how the U.S.-China trade war impacts drug costs, EU approval of ...

A new guideline for treating obesity in children and adolescents says medication can be helpful, but that health providers ...

As per Vantage Market Research, the surge in cloud computing is poised to inject substantial momentum into the health ...

The rapid increase in the use of glucagon-like peptide-1 receptor agonists for weight loss, diabetes management and ...

Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing ...

The Digital Therapeutics Market is valued at USD 4.8 Billion in 2022 and is expected to reach USD 18.72 Billion by 2030 at a CAGR of 30.08% over the forecast period 2023-2030.   Overview of the ...

The distinction between biological and chronological age is vital for risk assessment and interventions aimed at enhancing longevity and quality of life.

Cardiovascular risk factors, accelerated by depression and anxiety, increase a patient’s risk for end-stage renal disease, according to a study presented at the American College of Cardiology’s 2025 ...

Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, and Okava Pharmaceuticals, Inc.